Improving circulating tumor cells enumeration and characterization to predict outcome in first line chemotherapy mCRPC patients


INTRODUCTION There is a critical need of new surrogate markers for improving the therapeutic selection and monitoring of metastatic prostate cancer patients. Nowadays clinical management of these patients is been driven by biochemical and clinical parameters without enough accuracy to allow a real personalized medicine. The present study was conducted to go… (More)
DOI: 10.18632/oncotarget.18025